Early data from Clearmind's MEAI-based CMND-100 trial in alcohol use disorder will be reviewed in a June 10 webinar with Yale and Johns Hopkins.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.